Literature DB >> 1453236

Effects of dexamethasone on experimental atherosclerosis in cholesterol-fed rabbits.

M Naito1, M Yasue, K Asai, K Yamada, T Hayashi, M Kuzuya, C Funaki, N Yoshimine, F Kuzuya.   

Abstract

We studied the effects of a synthetic adrenocortical steroid, dexamethasone, on the development of experimental atherosclerosis in cholesterol-fed rabbits. Daily intramuscular injection of dexamethasone (0.125 mg/day) remarkably inhibited the aortic atherosclerosis induced by feeding a 1% cholesterol-rich diet for 8 weeks, although it aggravated diet-induced hyperlipidemia. Histologically, less foam cell accumulation was observed in the atherosclerotic lesions of the dexamethasone-treated rabbits as compared with the control animals. When rabbits were fed a normal chow diet for 10 weeks after receiving the 1% cholesterol-rich diet for 8 weeks, no regression of atherosclerotic lesions was observed with the daily injection of dexamethasone (0.125 mg/day); however, the drug again tended to inhibit further progression of atherosclerosis. The anti-atherogenic mechanism of dexamethasone may involve an inhibition of recruitment of blood monocytes and the insudation of atherogenic lipoproteins, mainly beta-very low density lipoprotein (beta-VLDL) in the present experiments, into the aortic intima, or it may involve a change in the size and structure of the lipoproteins, resulting in their decreased passage through the aortic endothelium into the intima.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453236     DOI: 10.3177/jnsv.38.255

Source DB:  PubMed          Journal:  J Nutr Sci Vitaminol (Tokyo)        ISSN: 0301-4800            Impact factor:   2.000


  9 in total

1.  Identification of a novel dexamethasone-sensitive RNA-destabilizing region on rat monocyte chemoattractant protein 1 mRNA.

Authors:  M Poon; B Liu; M B Taubman
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

Review 2.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

Review 3.  Lipoproteins and lipoprotein mimetics for imaging and drug delivery.

Authors:  C Shad Thaxton; Jonathan S Rink; Pratap C Naha; David P Cormode
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

4.  Dexamethasone inhibits activation of monocytes/macrophages in a milieu rich in 27-oxygenated cholesterol.

Authors:  Bo-Young Kim; Yonghae Son; Jeonga Lee; Jeongyoon Choi; Chi Dae Kim; Sun Sik Bae; Seong-Kug Eo; Koanhoi Kim
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

5.  Differential action of glucocorticoids on apolipoprotein E gene expression in macrophages and hepatocytes.

Authors:  Violeta Georgeta Trusca; Elena Valeria Fuior; Ioana Madalina Fenyo; Dimitris Kardassis; Maya Simionescu; Anca Violeta Gafencu
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

6.  Drug delivery to atherosclerotic plaques using superparamagnetic iron oxide nanoparticles.

Authors:  Jasmin Matuszak; Barbara Lutz; Aleksander Sekita; Jan Zaloga; Christoph Alexiou; Stefan Lyer; Iwona Cicha
Journal:  Int J Nanomedicine       Date:  2018-12-11

7.  Both transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP mice.

Authors:  Hanna E Auvinen; Yanan Wang; Hans Princen; Johannes A Romijn; Louis M Havekes; Johannes W A Smit; Onno C Meijer; Nienke R Biermasz; Patrick C N Rensen; Alberto M Pereira
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

Review 8.  Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation.

Authors:  Patrick W F Hadoke; Tiina Kipari; Jonathan R Seckl; Karen E Chapman
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

9.  Reformulating Small Molecules for Cardiovascular Disease Immune Intervention: Low-Dose Combined Vitamin D/Dexamethasone Promotes IL-10 Production and Atheroprotection in Dyslipidemic Mice.

Authors:  Laura Ospina-Quintero; Julio C Jaramillo; Jorge H Tabares-Guevara; José R Ramírez-Pineda
Journal:  Front Immunol       Date:  2020-04-24       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.